Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

miR-145 Antagonizes SNAI1-Mediated Stemness and Radiation Resistance in Colorectal Cancer.

Zhu Y, Wang C, Becker SA, Hurst K, Nogueira LM, Findlay VJ, Camp ER.

Mol Ther. 2018 Mar 7;26(3):744-754. doi: 10.1016/j.ymthe.2017.12.023. Epub 2018 Jan 4.

PMID:
29475734
2.

MicroRNAs and Their Impact on Breast Cancer, the Tumor Microenvironment, and Disparities.

Evans-Knowell A, LaRue AC, Findlay VJ.

Adv Cancer Res. 2017;133:51-76. doi: 10.1016/bs.acr.2016.08.003. Epub 2016 Sep 26. Review.

PMID:
28052821
3.

Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment.

McDonald LT, Russell DL, Kelly RR, Xiong Y, Motamarry A, Patel RK, Jones JA, Watson PM, Turner DP, Watson DK, Soloff AC, Findlay VJ, LaRue AC.

Neoplasia. 2015 May;17(5):434-48. doi: 10.1016/j.neo.2015.04.004.

4.

FLI1 expression is correlated with breast cancer cellular growth, migration, and invasion and altered gene expression.

Scheiber MN, Watson PM, Rumboldt T, Stanley C, Wilson RC, Findlay VJ, Anderson PE, Watson DK.

Neoplasia. 2014 Oct 23;16(10):801-13. doi: 10.1016/j.neo.2014.08.007. eCollection 2014 Oct.

5.

SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression.

Findlay VJ, Wang C, Nogueira LM, Hurst K, Quirk D, Ethier SP, Staveley O'Carroll KF, Watson DK, Camp ER.

Mol Cancer Ther. 2014 Nov;13(11):2713-26. doi: 10.1158/1535-7163.MCT-14-0207. Epub 2014 Sep 23.

6.

AGE metabolites: a biomarker linked to cancer disparity?

Foster D, Spruill L, Walter KR, Nogueira LM, Fedarovich H, Turner RY, Ahmed M, Salley JD, Ford ME, Findlay VJ, Turner DP.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2186-91. doi: 10.1158/1055-9965.EPI-14-0564. Epub 2014 Jul 22.

7.

Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer.

Findlay VJ, Wang C, Watson DK, Camp ER.

Cancer Gene Ther. 2014 May;21(5):181-7. doi: 10.1038/cgt.2014.15. Epub 2014 May 2. Review.

8.

Slug expression inhibits calcitriol-mediated sensitivity to radiation in colorectal cancer.

Findlay VJ, Moretz RE, Wang C, Vaena SG, Bandurraga SG, Ashenafi M, Marshall DT, Watson DK, Camp ER.

Mol Carcinog. 2014 Feb;53 Suppl 1:E130-9. doi: 10.1002/mc.22054. Epub 2013 Aug 31.

9.

MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer.

Guo QJ, Mills JN, Bandurraga SG, Nogueira LM, Mason NJ, Camp ER, Larue AC, Turner DP, Findlay VJ.

Breast Cancer Res. 2013;15(4):R70.

10.

Understanding the role of ETS-mediated gene regulation in complex biological processes.

Findlay VJ, LaRue AC, Turner DP, Watson PM, Watson DK.

Adv Cancer Res. 2013;119:1-61. doi: 10.1016/B978-0-12-407190-2.00001-0. Review.

PMID:
23870508
11.

Kaposi's sarcoma-associated herpesvirus suppression of DUSP1 facilitates cellular pathogenesis following de novo infection.

Qin Z, Dai L, Defee M, Findlay VJ, Watson DK, Toole BP, Cameron J, Peruzzi F, Kirkwood K, Parsons C.

J Virol. 2013 Jan;87(1):621-35. doi: 10.1128/JVI.01441-12. Epub 2012 Oct 24.

12.
13.

ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.

Smith AM, Findlay VJ, Bandurraga SG, Kistner-Griffin E, Spruill LS, Liu A, Golshayan AR, Turner DP.

Carcinogenesis. 2012 Mar;33(3):572-80. doi: 10.1093/carcin/bgs007. Epub 2012 Jan 9.

PMID:
22232738
14.

Prostate-Derived ETS Factor Regulates Epithelial-to-Mesenchymal Transition through Both SLUG-Dependent and Independent Mechanisms.

Findlay VJ, Turner DP, Yordy JS, McCarragher B, Shriver MR, Szalai G, Watson PM, Larue AC, Moussa O, Watson DK.

Genes Cancer. 2011 Feb;2(2):120-9. doi: 10.1177/1947601911410424.

15.

Slug expression enhances tumor formation in a noninvasive rectal cancer model.

Camp ER, Findlay VJ, Vaena SG, Walsh J, Lewin DN, Turner DP, Watson DK.

J Surg Res. 2011 Sep;170(1):56-63. doi: 10.1016/j.jss.2011.02.012. Epub 2011 Mar 23.

16.

Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression.

Turner DP, Findlay VJ, Moussa O, Semenchenko VI, Watson PM, LaRue AC, Desouki MM, Fraig M, Watson DK.

Prostate. 2011 Dec;71(16):1723-35. doi: 10.1002/pros.21389. Epub 2011 Mar 28.

17.

MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer.

Findlay VJ, Turner DP, Moussa O, Watson DK.

Cancer Res. 2008 Oct 15;68(20):8499-506. doi: 10.1158/0008-5472.CAN-08-0907.

18.

Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression.

Turner DP, Findlay VJ, Kirven AD, Moussa O, Watson DK.

Mol Biol Cell. 2008 Sep;19(9):3745-57. doi: 10.1091/mbc.E08-02-0154. Epub 2008 Jun 25.

19.

Defining ETS transcription regulatory networks and their contribution to breast cancer progression.

Turner DP, Findlay VJ, Moussa O, Watson DK.

J Cell Biochem. 2007 Oct 15;102(3):549-59. Review.

PMID:
17661355
20.

A novel role for human sulfiredoxin in the reversal of glutathionylation.

Findlay VJ, Townsend DM, Morris TE, Fraser JP, He L, Tew KD.

Cancer Res. 2006 Jul 1;66(13):6800-6.

21.

PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity.

Saavedra JE, Srinivasan A, Buzard GS, Davies KM, Waterhouse DJ, Inami K, Wilde TC, Citro ML, Cuellar M, Deschamps JR, Parrish D, Shami PJ, Findlay VJ, Townsend DM, Tew KD, Singh S, Jia L, Ji X, Keefer LK.

J Med Chem. 2006 Feb 9;49(3):1157-64.

PMID:
16451080
22.

A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins.

Townsend DM, Findlay VJ, Fazilev F, Ogle M, Fraser J, Saavedra JE, Ji X, Keefer LK, Tew KD.

Mol Pharmacol. 2006 Feb;69(2):501-8. Epub 2005 Nov 15.

23.

Sulfiredoxin: a potential therapeutic agent?

Findlay VJ, Tapiero H, Townsend DM.

Biomed Pharmacother. 2005 Aug;59(7):374-9. Review.

PMID:
16102934
24.

Oxidation of a eukaryotic 2-Cys peroxiredoxin is a molecular switch controlling the transcriptional response to increasing levels of hydrogen peroxide.

Bozonet SM, Findlay VJ, Day AM, Cameron J, Veal EA, Morgan BA.

J Biol Chem. 2005 Jun 17;280(24):23319-27. Epub 2005 Apr 11.

25.

A 2-Cys peroxiredoxin regulates peroxide-induced oxidation and activation of a stress-activated MAP kinase.

Veal EA, Findlay VJ, Day AM, Bozonet SM, Evans JM, Quinn J, Morgan BA.

Mol Cell. 2004 Jul 2;15(1):129-39.

26.

Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.

Findlay VJ, Townsend DM, Saavedra JE, Buzard GS, Citro ML, Keefer LK, Ji X, Tew KD.

Mol Pharmacol. 2004 May;65(5):1070-9.

27.

Distinct regulatory proteins control the graded transcriptional response to increasing H(2)O(2) levels in fission yeast Schizosaccharomyces pombe.

Quinn J, Findlay VJ, Dawson K, Millar JB, Jones N, Morgan BA, Toone WM.

Mol Biol Cell. 2002 Mar;13(3):805-16.

28.

Thioredoxin peroxidase is required for the transcriptional response to oxidative stress in budding yeast.

Ross SJ, Findlay VJ, Malakasi P, Morgan BA.

Mol Biol Cell. 2000 Aug;11(8):2631-42.

Supplemental Content

Loading ...
Support Center